admin

Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful real-world […]

In September 2026 Sasha Becejac, Digistain’s CCO, was invited to speak at On Targeted Molecular Oncology 2026 in Ankara, Türkiye, sharing the latest developments around Digistain […]

In September 2026 Sarah Bond, our COO for the MENA region, took part in The Future Health Dialogue roundtable hosted at Hub71 in Abu Dhabi, alongside […]

In July 2026 co-founder Professor Chris Phillips and COO Sabrina Ali met clinicians, researchers and pathology teams at major hospitals and innovation centres in Shanghai, including […]

In March 2026 we announced that Digistain has secured the rights to distribute geneType® across Southeast Asia. geneType is developed by Rhythm Biosciences, a publicly listed […]

In March 2026 Digistain was represented at the Thailand Board of Investment roundtable at the Thai Embassy in London. The evening brought together leaders from healthcare, […]

In February 2026 Digistain was selected as one of 27 companies by the EUREKA Investment Readiness Network to join a mission to South Summit Brazil, held […]

In December 2025 we showcased Digistain at BIGOSA 2025 alongside our partner, the Key Oncologics team. We engaged with hundreds of delegates and shared our latest […]